Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for diabetes and obesity.
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion. Recently,
Eli Lilly Stock's Correction Brings Opportunity
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same time,
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity treatments,
Jim Cramer Defends Eli Lilly and Company (LLY) Amid Concerns Over Drug Adherence, Cites Long-Term Health Potential
We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Ibj.com1d
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
FiercePharma3d
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
WBIW6h
Lilly Endowment grant to help strengthen early childhood education in the Indiana Uplands region
BLOOMINGTON– Lilly Endowment Inc., through the eighth phase of its Giving Indiana Funds for Tomorrow (GIFT VIII) initiative, has awarded a $7,834,000 Community Leadership ...
Leerink says Eli Lilly news causes concern about Tectonic’s TX45 success
Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...